DOGMA THERAPEUTICS
The pharmaceutical industry has struggled to identify small molecule inhibitors of PCSK9 function. This has been explained by the expansive but flat binding interface between PCSK9 and the LDL receptor, spanning nearly 800 square angstroms. To date, only monoclonal antibodies have been able to target this region of PCSK9. We have discovered bona fide small molecule inhibitors of PCSK9 function that are orally bioavailable across multiple preclinical species. Guided by dozens of high-resolution x-ray structures of our molecules bound to PCSK9, we have utilized structure-based design to achieve picomolar affinity.
DOGMA THERAPEUTICS
Industry:
Biotechnology Pharmaceutical
Founded:
2017-01-01
Address:
Boxford, Massachusetts, United States
Country:
United States
Website Url:
http://www.dogmatherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
3.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Google Apps For Business Google GStatic Google Static Content Google Cloud
Current Employees Featured
Founder
Investors List
JMCR Partners
JMCR Partners investment in Series A - Dogma Therapeutics
Viva BioInnovator
Viva BioInnovator investment in Series A - Dogma Therapeutics
Viva Ventures Biotech Fund
Viva Ventures Biotech Fund investment in Series A - Dogma Therapeutics
Official Site Inspections
http://www.dogmatherapeutics.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Dogma Therapeutics"
Dogma Therapeutics - Crunchbase Company Profile & Funding
Organization. Dogma Therapeutics . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Contact Email โฆSee details»
Dogma Therapeutics | Drugging the Undruggable
Dogma Therapeutics has discovered small molecule inhibitors of PCSK9. Guided by dozens of high-resolution x-ray structures of our molecules bound to PCSK9, we have utilized structure-based design to achieve picomolar affinity.See details»
Dogma Therapeutics 2025 Company Profile: Valuation, Investors ...
Dogma Therapeutics General Information Description. Operator of a biotechnology platform intended to develop small molecule compounds to lower cholesterol. The company's platform โฆSee details»
Dogma Therapeutics - Ownership and Business Overview | Mergr
United States, www.dogmatherapeutics.com. Profile M&A Activity (1) M&A Connections (1) Analytics Dogma Therapeutics has discovered bona fide small molecule inhibitors of PCSK9 โฆSee details»
Dogma Therapeutics - Overview, News & Competitors - ZoomInfo
View Dogma Therapeutics (www.dogmatherapeutics.com) location in Massachusetts, United States , revenue, industry and description. Find related and similar companies as well as โฆSee details»
Dogma Therapeutics - Funding, Financials, Valuation & Investors
Dogma is developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease. https://www.dogmatherapeutics.com/See details»
Dogma Therapeutics - Craft
Dogma Therapeutics is a company discovering bona fide small molecule inhibitors of PCSK9 function that are orally bioavailable across multiple preclinical species.See details»
Dogma Therapeutics, Inc. - Drug pipelines, Patents, Clinical
Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to RMB144.2 million โฆSee details»
Dogma Therapeutics - F6S
Similar companies Dogma Biotech Corp We accelerate new protein therapies through genetic minimalism Vivoryon Therapeutics Development of drugs for Alzheimer's disease Photys โฆSee details»
Dogma Therapeutics - VentureRadar
Similar Companies: Sun BioPharma USA Privately Held Sun BioPharma is developing small-molecule pharmaceuticals consisting of novel polyamine analogues and metal chelators, and โฆSee details»
DOGMA THERAPEUTICS, LLC Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for DOGMA THERAPEUTICS, LLC of Boxford, MA. Get the latest business insights from Dun & Bradstreet.See details»
Dogma Therapeutics - Company Profile - Tracxn
Dogma Therapeutics - Developer of small molecule inhibitors. Raised funding from 3 investors. Founded by Doug Daniels and Virendar Kaushik in the year 2015. Dogma Therapeutics has โฆSee details»
Dogma Therapeutics - Viva BioInnovator
Www.dogmatherapeutics.com. location. USA, Massachusetts, Boxford. modality. Small Molecule. Indications. Metabolic. Dogma Therapeutics has discovered bona fide small molecule โฆSee details»
Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme)
Dogma Therapeutics (Preclinical Oral PCSK9 Inhibitor Programme) General Information Description. An oral proprotein convertase subtilisin/kexin type 9 inhibitor program based in โฆSee details»
Dogma Therapeutics Reached the Acquisition Agreement with โฆ
Sep 17, 2020 For More Info, Please Visit www.dogmatherapeutics.com Previous Page๏ผ Quralis Included in the Fierce Biotech 2020 Fierce 15 List Next Page๏ผ VivaVision Submitted LFA1 โฆSee details»
Dogma Therapeutics Emerges from Stealth Mode and Announces โฆ
May 16, 2019 Massachusetts Biotechnology Council. 700 Technology Square, 5th Floor Cambridge, MA 02139 617.674.5100See details»
Dogma Therapeutics Announces Global Acquisition of Oral PCSK9 โฆ
CAMBRIDGE, Mass., Sept. 17, 2020 /PRNewswire/ -- Dogma Therapeutics ("Dogma") has reached an agreement for the acquisition of its oral PCSK9 program by AstraZeneca.Dogma โฆSee details»
Dogma Therapeutics - Contacts, Employees, Board Members
Dogma is developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease. https://www.dogmatherapeutics.com/See details»
Dogma Therapeutics Emerges from Stealth Mode and Announces โฆ
The word โundruggableโ has hampered pursuit of the most compelling biological targets, drawing from established opinion that pharmacological modulation was not possible. Scientists at โฆSee details»
Dogma Therapeutics, Inc. (Dogma Therapeutics, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ โฆ
May 1, 2023 Results Highlights for Interim Results ended 30 June 2024 Revenue reached RMB981.8 million Gross profit amounted to RMB339.1 million Net profit grew by 956.0 YoY to โฆSee details»